Abscess

Acelyrin, Inc. Lawsuit Reminder: Contact Robbins LLP for Information About Your Rights Against Acelyrin, Inc.

Retrieved on: 
Monday, December 4, 2023
LLP, Hidradenitis suppurativa, SLRN, HS, Person, Complaint, SAN, News, IPO, Patient, Abscess, Pharmaceutical industry

Acelyrin is a clinical biopharma company that focuses on developing and commercializing transformative medicines.

Key Points: 
  • Acelyrin is a clinical biopharma company that focuses on developing and commercializing transformative medicines.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • Specifically, izokibep failed to show statistically significant reduction in abscesses and inflammatory nodules in patients as compared to placebo.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Acelyrin, Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.

Investors Say Acelyrin (SLRN) Lied About Drug Candidate’s Progress - Hagens Berman

Retrieved on: 
Monday, December 4, 2023
Person, SLRN, Patient, HS, Hagens Berman, Abscess, SAN, Part, News, Pharmaceutical industry

SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now .
  • Investors learned the truth on Sept. 11, 2023, when Acelyrin announced disappointing top-line results from Part B of the Phase 2b/3 trial evaluating izokibep for the treatment of moderate to severe HS.
  • This news drove the price of Acelyrin shares plummeting $17.19 lower during the two trading days ended Sept. 13, 2023.
  • “We’re focused on investors’ losses and are investigating whether Acelyrin may have concealed data that did not support the hypothesized benefits of izokibep,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acelyrin, Inc. of Class Action Lawsuit and Upcoming Deadline – SLRN

Retrieved on: 
Monday, December 4, 2023
LLP, Hidradenitis suppurativa, Form, SLRN, Ext, HS, Court, Person, Register, News, Complaint, Pomerantz, Prior, IPO, Prospectus, Patient, Defendant, Abscess, District court, Action Replay, Security (finance)

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Acelyrin, Inc. (“Acelyrin” or the “Company”) (NASDAQ: SLRN) and certain officers.

Key Points: 
  • NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Acelyrin, Inc. (“Acelyrin” or the “Company”) (NASDAQ: SLRN) and certain officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

ACELYRIN SHAREHOLDER ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options

Retrieved on: 
Saturday, December 2, 2023
LLP, Form, SLRN, HS, Court, Register, News, Part, Advertising, IPO, Prospectus, Patient, Defendant, Abscess, Woman, Security (finance)

NEW YORK, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acelyrin, Inc. (“Acelyrin” or the “Company”) (NASDAQ: SLRN) and reminds investors of the January 16, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you suffered losses exceeding $50,000 investing in Acelyrin securities between May 4, 2023 and September 11, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Acelyrin’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

HAGENS BERMAN Alerts Acelyrin (SLRN) Investors to Pending Securities Fraud Class Action, Encourages Investors Who Suffered Substantial Losses to Contact Firm’s Attorneys

Retrieved on: 
Friday, December 1, 2023
SLRN, Patient, HS, Hagens Berman, Abscess, Person, Part, News, Pharmaceutical industry

Investors learned the truth on Sept. 11, 2023, when Acelyrin announced disappointing top-line results from Part B of the Phase 2b/3 trial evaluating izokibep for the treatment of moderate to severe HS.

Key Points: 
  • Investors learned the truth on Sept. 11, 2023, when Acelyrin announced disappointing top-line results from Part B of the Phase 2b/3 trial evaluating izokibep for the treatment of moderate to severe HS.
  • The company said izokibep failed to show statistically significant reduction in abscesses and inflammatory nodules in patients as compared to placebo.
  • This news drove the price of Acelyrin shares plummeting $17.19 lower during the two trading days ended Sept. 13, 2023.
  • “We’re focused on investors’ losses and are investigating whether Acelyrin may have concealed data that did not support the hypothesized benefits of izokibep,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ACELYRIN, Inc. (SLRN)

Retrieved on: 
Friday, December 1, 2023
Suite, Hidradenitis suppurativa, GPM, SLRN, HS, Court, News, Part, IPO, Patient, Defendant, Abscess

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • In May 2023, Acelyrin conducted its initial public offering (“IPO”), selling 30 million shares of common stock at $18 per share.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against Acelyrin, Inc.

Retrieved on: 
Thursday, November 30, 2023
Lead, Contract research organization, LLP, SLRN, Court, News, COPY, Insurance, Part, IPO, Patient, Abscess, District court, Pharmaceutical industry

The action charges Acelyrin with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges Acelyrin with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of Acelyrin’s materially misleading statements and omissions to the public, Acelyrin’s investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages Acelyrin investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.

ACELYRIN, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; January 16, 2023 deadline

Retrieved on: 
Tuesday, November 28, 2023
Hidradenitis suppurativa, SLRN, HS, News, Part, IPO, Patient, Defendant, Abscess, Pharmaceutical industry

LOS ANGELES, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ACELYRIN, Inc. (“Acelyrin” or the “Company”) (NASDAQ: SLRN) investors that a lawsuit filed on behalf of investors that purchased Acelyrin securities between May 4, 2023 and September 11, 2023, inclusive (the “Class Period”).

Key Points: 
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 844-767-8529 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The announcement revealed that izokibep did not achieve statistical significance in reducing abscesses and inflammatory nodules in patients compared to a placebo.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acelyrin (SLRN) Investors with Substantial Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed

Retrieved on: 
Monday, November 27, 2023
Person, SLRN, Patient, HS, Hagens Berman, Abscess, SAN, Part, News, Pharmaceutical industry

SAN FRANCISCO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now .
  • Acelyrin, Inc. (NASDAQ: SLRN) Securities Fraud Class Action:
    During the Class Period, Acelyrin said that evidence “continues to support the hypothesis that the high potency and small molecular size of izokibep can lead to clinically meaningful, differentiated benefits for patients[.
  • The company said izokibep failed to show statistically significant reduction in abscesses and inflammatory nodules in patients as compared to placebo.
  • This news drove the price of Acelyrin shares plummeting $17.19 lower during the two trading days ended Sept. 13, 2023.

ACELYRIN ONGOING DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Acelyrin To Contact Him Directly To Discuss Their Options

Retrieved on: 
Sunday, November 26, 2023
LLP, Form, SLRN, HS, Court, Register, News, Part, Advertising, IPO, Prospectus, Patient, Defendant, Abscess, Woman, Security (finance)

NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acelyrin, Inc. (“Acelyrin” or the “Company”) (NASDAQ: SLRN) and reminds investors of the January 16, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you purchased or acquired securities in Acelyrin between May 4, 2023 and September 11, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Acelyrin’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.